08 April 2019

Amedeo Smart

Independent Medical Education


Subscriber: th..@boehringer-ingelheim.com

HIV Infection

08 April 2019 | n=62

  1. Kay A, Moser C, McKhann A, Vargas M, et al.
    sST2 levels are not predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression.
    AIDS 2019.

  2. Remien RH, Stirratt MJ, Nguyen N, Robbins RN, et al.
    Mental health and HIV/AIDS: the need for an integrated response.
    AIDS 2019.

  3. Davey DLJ, Bekker LG, Gomba Y, Coates T, et al.
    Modelling the potential impact of providing pre-exposure prophylaxis (PrEP) in pregnant and breastfeeding women in South Africa.
    AIDS 2019.

  4. Enns B, Krebs E, Mathews WC, Moore RD, et al.
    Heterogeneity in the costs of medical care among people living with HIV/AIDS in the United States.
    AIDS 2019.

  5. Jin F, Vajdic CM, Law M, Amin J, et al.
    Incidence and time trends of anal cancer among people living with HIV in Australia.
    AIDS 2019.

  6. Alessandri-Gradt E, Unal G, Leoz M, Plantier JC, et al.
    Virological response to INSTI-based antiretroviral combinations in HIV-1 group O infected patients.
    AIDS 2019.

  7. Skerritt L, Boileau NT.
    Correspondence: behavioural changes following HIV seroconversion during the historical expansion of HIV treatment in the United States.
    AIDS 2019;33:1102-1103.

  8. Ashare RL, Thompson M, Leone F, Metzger D, et al.
    Differences in the rate of nicotine metabolism among smokers with and without HIV.
    AIDS 2019;33:1083-1088.

  9. Moyo S, Gaseitsiwe S, Zahralban-Steele M, Maruapula D, et al.
    Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    AIDS 2019;33:1073-1082.

  10. Thomas R, Friebel R, Barker K, Mwenge L, et al.
    Work and home productivity of people living with HIV in Zambia and South Africa.
    AIDS 2019;33:1063-1071.

  11. Whelton SP, Deal JA, Zikusoka M, Jacobson LP, et al.
    Associations between lipids and subclinical coronary atherosclerosis.
    AIDS 2019;33:1053-1061.

  12. Hua S, Scott JM, Hanna DB, Haberlen SA, et al.
    Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection.
    AIDS 2019;33:1043-1052.

  13. Albrecht S, Franzeck FC, Mapesi H, Hatz C, et al.
    Age-related comorbidities and mortality in people living with HIV in rural Tanzania.
    AIDS 2019;33:1031-1041.

  14. Webel AR, Jenkins T, Vest M, Oliveira VHF, et al.
    Cardiorespiratory fitness is associated with inflammation and physical activity in HIV+ adults.
    AIDS 2019;33:1023-1030.

  15. Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, et al.
    Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up.
    AIDS 2019;33:1013-1022.

  16. Sessa L, Reddel S, Manno E, Quagliariello A, et al.
    Distinct gut microbiota profile in antiretroviral therapy-treated perinatally HIV-infected patients associated with cardiac and inflammatory biomarkers.
    AIDS 2019;33:1001-1011.

  17. Lupo J, Germi R, Lancar R, Algarte-Genin M, et al.
    Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era.
    AIDS 2019;33:993-1000.

  18. Cote SC, Stilla A, Burke Schinkel SC, Berthoud TK, et al.
    IL-7-induced proliferation of peripheral Th17 cells is impaired in HAART-controlled HIV infection.
    AIDS 2019;33:985-991.

  19. Kim BH, Kelschenbach J, Borjabad A, Hadas E, et al.
    Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders in EcoHIV-infected mice.
    AIDS 2019;33:973-984.

  20. Guardo AC, Zarama A, Gonzalez T, Bargallo ME, et al.
    Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients.
    AIDS 2019;33:965-972.

  21. Gorwood J, Bourgeois C, Mantecon M, Atlan M, et al.
    Impact of HIV/simian immunodeficiency virus infection and viral proteins on adipose tissue fibrosis and adipogenesis.
    AIDS 2019;33:953-964.

  22. Milne RS, Silverman RA, Beck IA, Mckernan-Mullin J, et al.
    Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
    AIDS 2019;33:941-951.

  23. Montoya JL, Jankowski CM, O'Brien KK, Webel AR, et al.
    Evidence-informed practical recommendations for increasing physical activity among persons living with HIV.
    AIDS 2019;33:931-939.

  24. Wearne N, Hung R, Bohmer R, Spies R, et al.
    Kidney disease in africans with hiv and tuberculosis.
    AIDS 2019.

  25. Li Y, Wang Z, Cheng Y, Becker JT, et al.
    Neuropsychological changes in efavirenz switch regimens in the multicenter AIDS cohort study.
    AIDS 2019.

  26. Huang YS, Liu CE, Lin SP, Lee CH, et al.
    Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia.
    AIDS 2019.

  27. Xu W, Pu J, Su S, Hua C, et al.
    Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
    AIDS 2019.

  28. Kaewpreedee P, Boonrat P, Tansiri Y, Rowland-Jones SL, et al.
    Dimorphism in the T-cell receptor constant region affects T-cell function, phenotype and HIV outcome.
    AIDS 2019.

  29. Buckey JC, Fellows AM, Magohe A, Maro I, et al.
    Hearing complaints in HIV infection originate in the brain not the ear.
    AIDS 2019.

  30. Le Roux SM, Abrams EJ, Nguyen KK, Myer L, et al.
    HIV Incidence during breastfeeding and mother-to-child transmission in cape town, south africa.
    AIDS 2019.

  31. Santosa WB, Staines-Urias E, Tshivuila-Matala COO, Norris SA, et al.
    Perinatal outcomes associated with maternal HIV and antiretroviral therapy in pregnancies with accurate gestational age in South Africa.
    AIDS 2019.

  32. Sharma S, Schlusser KE, Torre P, Tambussi G, et al.
    The benefit of immediate compared to deferred ART on CD4+ Cell count recovery in early HIV infection.
    AIDS 2019.

  33. Wilson KS, Mugo C, Moraa H, Onyango A, et al.
    Health provider training is associated with improved engagement in HIV care among adolescents and young adults in kenya.
    AIDS 2019.

  34. Kemp CG, Lipira LL, Huh D, Nevin PE, et al.
    HIV stigma and viral load among African-American women receiving treatment for HIV: A longitudinal analysis.
    AIDS 2019.

  35. Vibholm LK, Konrad CV, Schleimann MH, Frattari G, et al.
    Effects of 24 Week Toll-Like Receptor 9 Agonist Treatment in HIV-1+ Individuals: a single-arm, phase 1B/2A trial.
    AIDS 2019.

  36. Pintye J, Drake AL, Begnel E, Kinuthia J, et al.
    Acceptability and outcomes of distributing HIV self-tests for male partner testing in Kenyan maternal child health and family planning clinics.
    AIDS 2019.

  37. Bansi-Matharu L, Loria GR, Cole SR, Mugerwa H, et al.
    Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators.
    AIDS 2019.

  38. Kwon M, Bailen R, Balsalobre P, Jurado M, et al.
    Allogeneic stem cell transplantation in HIV-1 infected patients with high-risk hematological disorders.
    AIDS 2019.

  39. Gupta SK, Post FA, Arribas JR, Jr JJE, et al.
    Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials.
    AIDS 2019.

  40. Zhao D, Ding Y, Lin H, Chen X, et al.
    Mitochondrial haplogroups N9 and G are associated with metabolic syndrome among HIV-infected patients in China.
    AIDS Res Hum Retroviruses 2019.

  41. Matsunaga A, Oka M, Iijima K, Shimura M, et al.
    A quantitative system for monitoring blood-circulating viral protein R of human immunodeficiency virus-1 detected a possible link with pathogenic indices.
    AIDS Res Hum Retroviruses 2019.

  42. Gonese E, Kilmarx P, van Schalkwyk C, Grebe E, et al.
    Evaluation of the performance of three biomarker assays for recent HIV infection using a well-characterized HIV-1 subtype C incidence cohort.
    AIDS Res Hum Retroviruses 2019.

  43. Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, et al.
    Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Ann Intern Med 2019.

  44. Thao LTP, Wolbers M, Heemskerk AD, Thi Hoang Mai N, et al.
    Dynamic prediction of death in patients with tuberculous meningitis using time-updated Glasgow coma score and plasma sodium measurements.
    Clin Infect Dis 2019.

  45. Bertisch B, Brezzi M, Negro F, Mullhaupt B, et al.
    Very low hepatitis C viral loads in treatment-naive persons: do they compromise hepatitis C virus antigen testing?
    Clin Infect Dis 2019.

  46. Gupta A, Swindells S, Kim S, Hughes MD, et al.
    Feasibility of Identifying Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease.
    Clin Infect Dis 2019.

  47. Githinji LN, Gray DM, Hlengwa S, Machemedze T, et al.
    Longitudinal changes in Spirometry in perinatally HIV-infected South African adolescents on antiretroviral therapy.
    Clin Infect Dis 2019.

  48. Moscicki AB, Karalius B, Tassiopoulos K, Yao TJ, et al.
    Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth.
    Clin Infect Dis 2019.

  49. Thrift AP, Kramer JR, Hartman CM, Royse K, et al.
    Risk and predictors of esophageal and stomach cancers in HIV-infected veterans: A matched cohort study.
    J Acquir Immune Defic Syndr 2019.

  50. Vannappagari V, Thorne C.
    Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.
    J Acquir Immune Defic Syndr 2019.

  51. Kalayjian RC, Robertson KR, Albert JM, Fichthenbaum CJ, et al.
    Plasma Cystatin C Associates with HIV-Associated Neurocognitive Disorder but is a Poor Diagnostic Marker in Antiretroviral Therapy Treated Individuals.
    J Acquir Immune Defic Syndr 2019.

  52. Brittain K, Mellins CA, Remien RH, Phillips TK, et al.
    Impact of HIV-status disclosure on HIV viral load in pregnant and postpartum women on antiretroviral therapy.
    J Acquir Immune Defic Syndr 2019.

  53. Gonciulea A, Wang R, Althoff KN, Estrella MM, et al.
    Proteinuria is Associated with Increased Risk of Fragility Fracture in Men With or at Risk for HIV infection Proteinuria and Fracture Risk Association.
    J Acquir Immune Defic Syndr 2019.

  54. Sykes W, van den Berg K, Jacobs G, Jauregui A, et al.
    Discovery of "false Elite Controllers": HIV antibody-positive RNA-negative blood donors found to be on antiretroviral treatment.
    J Infect Dis 2019.

  55. Morrow M, Mawhinney S, Coyle RP, Coleman SS, et al.
    Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV.
    J Infect Dis 2019.

  56. Schwetz TA, Calder T, Rosenthal E, Kattakuzhy S, et al.
    Opioids and Infectious Diseases: A Converging Public Health Crisis.
    J Infect Dis 2019.

  57. Price MA, Rida W, Kilembe W, Karita E, et al.
    HIV-1 viral control varies by viral subtype in a large cohort of African adults with incident HIV-1 infection.
    J Infect Dis 2019.

  58. Alidjinou EK, Deldalle J, Robineau O, Hallaert C, et al.
    Routine drug resistance testing in proviral HIV-1 DNA: prevalence of stop codons and hypermutation, and associated factors.
    J Med Virol 2019.

  59. Nguyen HT, Alsahafi N, Finzi A, Sodroski JG, et al.
    Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function.
    J Virol 2019.

  60. Hanke K, Faria NR, Kuhnert D, Pouran Yousef K, et al.
    Reconstruction of the genetic history and the current spread of HIV-1 subtype A in Germany.
    J Virol 2019.

  61. Caskey M, Klein F, Nussenzweig MC.
    Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.
    Nat Med 2019;25:547-553.

  62. Naidoo L, Mzobe Z, Jin SW, Rajkoomar E, et al.
    Nef-mediated inhibition of NFAT following TCR stimulation differs between HIV-1 subtypes.
    Virology 2019;531:192-202.


Display articles in


Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:



Amedeo HIV Infection

Five-Week Literature

15 July 2019

08 July 2019

01 July 2019

24 June 2019

17 June 2019


08 April 2019

Multidisciplinary Journal Club

    No data available 2019-04-08.


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016